Go Pro
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel
LON:GSK

GSK Q1 Earnings Report

GSK logo
GBX 2,014.41 +31.41 (+1.58%)
As of 08:35 AM Eastern
ProfileEarnings HistoryForecast

GSK EPS Results

Actual EPS
GBX 46.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GSK Revenue Results

Actual Revenue
$7.63 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GSK Announcement Details

Quarter
Q1
Date
4/29/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GSK Earnings Headlines

GSK (LON:GSK) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell?
July 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30871754
Dodge & Cox lifts GSK stake above 5% as institutional backing grows
June 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/dodge-cox-lifts-gsk-stake-above-5-as-institutional-backing-grows?utm_source=marketbeat.com&utm_medium=referral
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
July 7 at 1:00 AM  |  InvestorPlace (Ad)
Spero Therapeutics and GSK Announce FDA Approval of Utebzi, the First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections in the US
June 17, 2026  |  quiverquant.comQ
GSK to acquire Boston cancer therapy company for $10.6B
June 9, 2026  |  bizjournals.comhttps://www.bizjournals.com/philadelphia/news/2026/06/09/gsk-nuvalent-boston-cancer-therapy-philadelphia.html
Mizuho’s Jared Holz on GSK’s plan to acquire Nuvalent for $10.6 billion
June 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/mizuho-s-jared-holz-on-gsk-s-plan-to-acquire-nuvalent-for-106-billion/vi-AA25clfD
See More GSK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GSK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GSK and other key companies, straight to your email.

About GSK

GSK (LON:GSK), together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

View GSK Profile
Earnings Tools